## Lars Agreus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5280178/publications.pdf Version: 2024-02-01



LADS ACDEUS

#	Article	IF	CITATIONS
1	Large-scale association analyses identify host factors influencing human gut microbiome composition. Nature Genetics, 2021, 53, 156-165.	21.4	676
2	High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report. Scandinavian Journal of Gastroenterology, 2005, 40, 275-285.	1.5	422
3	Non-ulcer Dyspepsia and Duodenal Eosinophilia: An Adult Endoscopic Population-Based Case-Control Study. Clinical Gastroenterology and Hepatology, 2007, 5, 1175-1183.	4.4	277
4	Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut, 2007, 56, 615-620.	12.1	249
5	Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. American Journal of Gastroenterology, 2001, 96, 2905-2914.	0.4	224
6	Peptic Ulcer Disease in a General Adult Population. American Journal of Epidemiology, 2006, 163, 1025-1034.	3.4	163
7	Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scandinavian Journal of Gastroenterology, 2012, 47, 136-147.	1.5	136
8	Anxiety Is Linked to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up Study. Gastroenterology, 2015, 148, 928-937.	1.3	128
9	Functional variants in the sucrase–isomaltase gene associate with increased risk of irritable bowel syndrome. Gut, 2018, 67, 263-270.	12.1	120
10	Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut, 2011, 60, 1671-1677.	12.1	109
11	Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. Scandinavian Journal of Gastroenterology, 2008, 43, 1448-1455.	1.5	102
12	Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. American Journal of Gastroenterology, 2000, 95, 1439-1447.	0.4	101
13	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut, 2015, 64, 1774-1782.	12.1	97
14	The Cost of Gastro-Oesophageal Reflux Disease, Dyspepsia and Peptic Ulcer Disease in Sweden. Pharmacoeconomics, 2002, 20, 347-355.	3.3	89
15	Transition from childhood to adulthood in coeliac disease: the Prague consensus report. Gut, 2016, 65, 1242-1251.	12.1	85
16	Colonic spirochetosis is associated with colonic eosinophilia and irritable bowel syndrome in a general population in Sweden. Human Pathology, 2015, 46, 277-283.	2.0	81
17	Reproducibility and validity of a postal questionnaire: The abdominal symptom study. Scandinavian Journal of Primary Health Care, 1993, 11, 252-262.	1.5	78
18	Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals. Scientific Reports, 2020, 10, 14977.	3.3	78

LARS AGREUS

#	Article	IF	CITATIONS
19	No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut, 2020, 69, 1076-1084.	12.1	76
20	Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group. Scandinavian Journal of Pain, 2016, 11, 111-122.	1.3	73
21	Socio-economic Factors, Health Care Consumption and Rating of Abdominal Symptom Severity. A Report from The Abdominal Symptom Study. Family Practice, 1993, 10, 152-163.	1.9	58
22	Assessment of normal bowel habits in the general adult population: the Popcol study. Scandinavian Journal of Gastroenterology, 2010, 45, 556-566.	1.5	57
23	Challenges in managing dyspepsia in general practice. BMJ: British Medical Journal, 1997, 315, 1284-1288.	2.3	57
24	Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology, 2018, 155, 168-179.	1.3	55
25	Epidemiology of reflux symptoms and GORD. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2013, 27, 325-337.	2.4	50
26	Celiac disease, eosinophilic esophagitis and gastroesophageal reflux disease, an adult population-based study. Scandinavian Journal of Gastroenterology, 2013, 48, 808-814.	1.5	50
27	Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis. Gut, 2017, 66, 421-428.	12.1	50
28	Genetic variants in <i>CDC42</i> and <i>NXPH1</i> as susceptibility factors for constipation and diarrhoea predominant irritable bowel syndrome. Gut, 2014, 63, 1103-1111.	12.1	49
29	A nationwide cohort study of the incidence of microscopic colitis in Sweden. Alimentary Pharmacology and Therapeutics, 2019, 49, 1395-1400.	3.7	49
30	miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. Scientific Reports, 2017, 7, 14680.	3.3	46
31	Duodenal eosinophilia is associated with functional dyspepsia and new onset gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2019, 50, 24-32.	3.7	46
32	Stool frequency is associated with gut microbiota composition. Gut, 2017, 66, 559-560.	12.1	45
33	Hill classification is superior to the axial length of a hiatal hernia for assessment of the mechanical anti-reflux barrier at the gastroesophageal junction. Endoscopy International Open, 2016, 04, E311-E317.	1.8	44
34	A negativeHelicobacter pyloriserology test is more reliable for exclusion of premalignant gastric conditions than a negative test for currentH. pyloriinfection: A report on histology andH. pyloridetection in the general adult population. Scandinavian Journal of Gastroenterology, 2005, 40, 302-311.	1.5	43
35	A randomly selected population sample undergoing colonoscopy. European Journal of Gastroenterology and Hepatology, 2014, 26, 268-275.	1.6	42
36	Clinical use of proton-pump inhibitors but not H <sub>2</sub> -blockers or antacid/alginates raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. Scandinavian Journal of Gastroenterology, 2009, 44, 564-570.	1.5	41

Lars Agreus

#	Article	IF	CITATIONS
37	Peptic ulcer disease. BMJ: British Medical Journal, 2019, 367, 15495.	2.3	41
38	Prevalence of colonic neoplasia and advanced lesions in the normal population: a prospective population-based colonoscopy study. Scandinavian Journal of Gastroenterology, 2012, 47, 184-190.	1.5	36
39	<i>TRPM8</i> polymorphisms associated with increased risk of IBS-C and IBS-M. Gut, 2017, 66, 1725-1727.	12.1	36
40	The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis. Clinical and Translational Gastroenterology, 2019, 10, e00065.	2.5	35
41	Antimicrobial Susceptibility of Helicobacter pylori Strains in a Random Adult Swedish Population. Helicobacter, 2006, 11, 224-230.	3.5	34
42	Towards a healthy stomach? <i>Helicobacter pylori</i> prevalence has dramatically decreased over 23 years in adults in a Swedish community. United European Gastroenterology Journal, 2016, 4, 686-696.	3.8	33
43	Symptomatic Diverticulosis Is Characterized By Loose Stools. Clinical Gastroenterology and Hepatology, 2016, 14, 1763-1770.e1.	4.4	30
44	Faecal microbiota composition associates with abdominal pain in the general population. Gut, 2018, 67, gutjnl-2017-314792.	12.1	29
45	Gastric Microbiota in a Low–Helicobacter pylori Prevalence General Population and Their Associations With Gastric Lesions. Clinical and Translational Gastroenterology, 2020, 11, e00191.	2.5	29
46	Diverticulosis, Symptoms and Colonic Inflammation: A Population-Based Colonoscopy Study. American Journal of Gastroenterology, 2019, 114, 500-510.	0.4	26
47	Use of tobacco products and gastrointestinal morbidity: an endoscopic population-based study (the) Tj ETQq1 1	0.784314	l rgBT /Ove
48	Genome-Wide Association Study Identifies Two Novel Genomic Regions in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2014, 109, 770-772.	0.4	23
49	Differential clustering of fecal and mucosaâ€associated microbiota in †healthy' individuals. Journal of Digestive Diseases, 2018, 19, 745-752.	1.5	23
50	Lymphocytic oesophagitis, a condition in search of a disease?: Table 1. Gut, 2012, 61, 1776.1-1776.	12.1	22
51	Discriminant and convergent validity of the GSRSâ€ŀBS symptom severity measure for irritable bowel syndrome: A population study. United European Gastroenterology Journal, 2020, 8, 284-292.	3.8	22
52	Abuse in Women and Men with and without Functional Gastrointestinal Disorders. Digestive Diseases and Sciences, 2008, 53, 1856-1864.	2.3	20
53	Gastrointestinal recall questionnaires compare poorly with prospective patient diaries for gastrointestinal symptoms: data from population and primary health centre samples. European Journal of Gastroenterology and Hepatology, 2019, 31, 163-169.	1.6	18
54	Role of smoking in functional dyspepsia and irritable bowel syndrome: three random populationâ€based studies. Alimentary Pharmacology and Therapeutics, 2021, 54, 32-42.	3.7	18

LARS AGREUS

#	Article	IF	CITATIONS
55	Management of gastro-oesophageal reflux disease in primary care: a European observational study. Current Medical Research and Opinion, 2009, 25, 2777-2784.	1.9	17
56	Increased Risk of Barrett's Esophagus Among Individuals Born Preterm or Small for Gestational Age. Clinical Gastroenterology and Hepatology, 2013, 11, 790-794.	4.4	16
57	GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. Cell Genomics, 2021, 1, 100069.	6.5	15
58	A GWAS meta-analysis suggests roles for xenobiotic metabolism and ion channel activity in the biology of stool frequency. Gut, 2017, 66, 756-758.	12.1	14
59	Duodenal eosinophilia and the link to anxiety: A populationâ€based endoscopic study. Neurogastroenterology and Motility, 2021, 33, e14109.	3.0	14
60	Value of the "Test & Treat―Strategy for Uninvestigated Dyspepsia at Low Prevalence Rates of <i>Helicobacter pylori</i> in the Population. Helicobacter, 2016, 21, 186-191.	3.5	11
61	Identifying clinically relevant sliding hiatal hernias: a population-based endoscopy study. Scandinavian Journal of Gastroenterology, 2018, 53, 657-660.	1.5	11
62	Acute upper gastrointestinal bleeding. BMJ: British Medical Journal, 2018, 363, k4023.	2.3	10
63	How individuals with the irritable bowel syndrome describe their own symptoms before formal diagnosis. Upsala Journal of Medical Sciences, 2015, 120, 276-279.	0.9	9
64	Approach to managing undiagnosed chest pain: could gastroesophageal reflux disease be the cause?. Canadian Family Physician, 2007, 53, 261-6.	0.4	9
65	Consultation rates and characteristics of gastro-oesophageal reflux disease in primary care: A European observational study. European Journal of General Practice, 2009, 15, 154-160.	2.0	8
66	Prospective Diary Evaluation of Unexplained Abdominal Pain and Bowel Dysfunction: A Population-Based Colonoscopy Study. Digestive Diseases and Sciences, 2011, 56, 1444-1451.	2.3	8
67	4-Aminobutyrate Aminotransferase (ABAT): Genetic and Pharmacological Evidence for an Involvement in Gastro Esophageal Reflux Disease. PLoS ONE, 2011, 6, e19095.	2.5	8
68	Decreased Number of Duodenal Endocrine Cells with Unaltered Serotonin-Containing Cells in Functional Dyspepsia. American Journal of Gastroenterology, 2016, 111, 1852-1853.	0.4	7
69	lleocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study. Clinical and Translational Gastroenterology, 2021, 12, e00296.	2.5	7
70	Structured Diagnostic and Treatment Approach Versus the Usual Primary Care Approach in Patients With Gastroesophageal Reflux Disease. Journal of Clinical Gastroenterology, 2013, 47, e65-e73.	2.2	6
71	Effects of Psychology and Extragastrointestinal Symptoms on Health Care Use by Subjects With and Without Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 847-854.e1.	4.4	5
72	Predictors and Non-Predictors of Symptom Relief in Dyspepsia Consultations in Primary Care. Digestive Diseases, 2008, 26, 248-255.	1.9	4

LARS AGREUS

#	Article	IF	CITATIONS
73	Colonoscopy findings in high-risk individuals compared to an average-risk control population. Scandinavian Journal of Gastroenterology, 2015, 50, 866-874.	1.5	4
74	Gastro-oesophageal reflux disease redefined: Implications for primary care. European Journal of General Practice, 2007, 13, 214-215.	2.0	2
75	Structured management strategy versus usual care for gastroesophageal reflux disease: rationale for pooled analysis of five European cluster-randomized trials. Therapeutic Advances in Gastroenterology, 2011, 4, 11-26.	3.2	2
76	International primary care snapshots: Sweden and Lebanon. British Journal of General Practice, 2015, 65, 28-29.	1.4	2
77	Response to Tursi. American Journal of Gastroenterology, 2019, 114, 1350-1351.	0.4	2
78	Clusters of community-dwelling individuals empirically derived from stool diaries correspond with clinically meaningful outcomes. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	1
79	Editorial: the overlap between dyspepsia and gastroâ€oesophageal reflux—is duodenal eosinophilia the missing link? Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 455-456.	3.7	Ο
80	Z-line alterations and gastroesophageal reflux: an endoscopic population-based prospective cohort study. Scandinavian Journal of Gastroenterology, 2019, 54, 1065-1069.	1.5	0
81	Response to Zidar et al. American Journal of Gastroenterology, 2019, 114, 1348-1349.	0.4	0
82	Editorial: tobacco use in functional dyspepsia—another smoking gun? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 79-79.	3.7	0